HER2 positive (non-luminal) DCIS had a concordance rate of 86.5% (90 out of 104 patients) between biopsy and surgery, which ranked the highest among five molecular subtypes. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.